Evidence map›Paper›PMID 36757637›Full record

ReviewCardiology and therapy2023

Risk and Management of Patients with Cancer and Heart Disease.

Loreena Hill, Bruno Delgado, Ekaterini Lambrinou, Tara Mannion, Mark Harbinson, Claire McCune

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cardiology and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 5 countries.

Loreena HillSchool of Nursing and Midwifery, Queen's University, 97 Lisburn Road, Belfast, BT9 7BL, UK. l.hill@qub.ac.uk.
Bruno DelgadoCardiology Department, University Hospital Centre of Oporto, Stº António Hospital, Oporto, Portugal.
Ekaterini LambrinouDepartment of Nursing, Cyprus University of Technology, Limassol, Cyprus.
Tara MannionBeaumont Hospital, Dublin, Ireland.
Mark HarbinsonCentre for Public Health, Queen's University Belfast, Belfast, UK.
Claire McCuneSchool of Medicine Dentistry and Biomedical Sciences, Queen's University, Belfast, UK.
Queen's University Belfast · GBCyprus University of Technology · CYUniversidade Católica Portuguesa · PTUniversity College Dublin · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer and cardiovascular disease are two of the leading causes of global mortality and morbidity. Medical research has generated powerful lifesaving treatments for patients with cancer; however, such treatments may sometimes be at the expense of the patient's myocardium, leading to heart failure. Anti-cancer drugs, including anthracyclines, can result in deleterious cardiac effects, significantly impacting patients' functional capacity, mental well-being, and quality of life. Recognizing this, recent international guidelines and expert papers published recommendations on risk stratification and care delivery, including that of cardio-oncology services. This review will summarize key evidence with a focus on anthracycline therapy, providing clinical guidance for the non-oncology professional caring for a patient with cancer and heart failure.

Indexed as

AnthracyclineCardiotoxicityHeart failureRisk stratification

Identifiers

PMID36757637
PMCPMC10209380
OpenAlexW4319656317

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.